The real-world numbers on GLP-1 persistence are brutal and consistent. A 2025 analysis of US electronic health records found 64.8% of patients without diabetes discontinue within one year. A Danish population study presented at EASD 2025 tracked the decay curve precisely: 18% gone at three months, 31% at six, 42% at nine, 52% at twelve. Even tirzepatide, the best-retained agent in the class, loses half its patients inside a year.

For a longevity clinic, those numbers describe something different than they do for a weight-loss clinic. Your GLP-1 or peptide protocol is not a standalone product — it is one strand of a membership relationship that includes panels, consults, and a multi-year optimization plan. When the injectable protocol lapses, the data shows what tends to follow: the check-ins stop, the labs stop, and the membership quietly dies with the prescription. The Thinking Robot builds Revenue Recovery Infrastructure for exactly this failure mode, with Aurora, our vitality specialist, anchoring the Biohacking and Longevity deployments.

Why Discontinuation Is a Cadence Problem, Not a Motivation Problem

Look at where the Danish curve breaks: months three, six, and nine. Those are not random. They map to the points where the protocol's logistics get hard — a refill that requires a renewed authorization, a titration question nobody answered, a side-effect week with no check-in scheduled, a lab draw that never got booked. The patient does not decide to quit. The program simply stops reaching them, and silence becomes the default.

One published register note is worth keeping on the wall: younger patients (18–29) were 48% more likely to discontinue in year one. The demographic most comfortable buying longevity services digitally is also the demographic most likely to drift when the touch cadence slips. They will not call you to say they are drifting. The cadence has to find them.

The Cadence That Keeps a Program Alive

In the deployments we engineer, the GLP-1 and peptide retention spine is a scheduled sequence of touches, executed automatically and escalated to humans when a real conversation is needed:

• Refill horizon tracking. Every active protocol carries a known supply runway. Outreach begins seven to ten days before the runway ends — by voice and SMS — so the renewal consult is booked before the last dose, not after a two-week gap has already reset the habit.

• Check-in anchoring at the decay points. Proactive contact in weeks 10–12, around month six, and before month nine — the exact intervals where the discontinuation curve steepens. A five-minute call that surfaces a side-effect concern or a dosing question is the cheapest retention instrument in the building.

• Lab-to-consult bridging. Quarterly panels only retain members if the review consult gets scheduled. The automation books the review the moment results post, instead of waiting for the member to remember.

• Lapse recovery inside 30 days. A member who misses a refill window gets a structured, polite recovery sequence immediately — because every week of silence makes the restart conversation harder.

None of this replaces your clinical team. It is the connective tissue underneath them — the part of the job that is pure logistics and timing, executed without fatigue, so your coordinators spend their hours on the conversations that actually require judgment. This is Pillar 3, the Reactivation discipline, applied before the patient ever goes fully dormant.

A Note on the Compounds Members Ask About

One operational detail matters more in this vertical than any other: members call asking about compounds that are still investigational. The correct front-desk behavior is intake-only — recognize the term, capture the interest, book the consult with the clinician, and make no claims about efficacy, dosing, or availability. A voice agent that improvises an answer about an unapproved compound is a regulatory liability wearing a friendly voice. Ours are built to hold that line precisely, and your medical director should verify that any vendor's agent does the same. The broader compliance checklist lives in our HIPAA-Compliant agent overview.

The Math at Membership Scale

Take a clinic with 200 members on GLP-1 or peptide protocols folded into memberships averaging $8,500 a year — the 2025 average annual revenue per member for membership-based longevity clinics. At the published 52% twelve-month discontinuation rate, 104 protocols lapse this year. If protocol lapse converts to membership churn even a third of the time, that is roughly 35 members and $297,500 in annual recurring revenue exiting through a scheduling gap. A cadence that recovers even one in five of those at-risk members returns about $59,500 a year — against a system whose entire job is making phone calls on time.

Run your own version of that math with your member count and your average membership value. If the leak is five figures, the cadence pays for itself. If it is not, we will tell you so.

References

• Medscape, Real-World Study Finds Over 50% Stop GLP-1s Within 1 Year — EASD 2025 Danish population study (medscape.com, 2025)

• Truveta Research, ISPOR 2025: drivers of GLP-1 RA discontinuation, EHR analysis (truveta.com, 2025)

• AJMC, GLP-1 RA Adherence Shows Drop-Off After 1 Year (ajmc.com, 2025)

• ISPOR 2025, Discontinuation Rates of Once-Weekly GLP-1 Receptor Agonists in Type 2 Diabetes (ispor.org, 2025)

• Altos Consulting Group, longevity clinic membership revenue benchmarks (altosconsultinggroup.com, 2026)

Next Step

If your premium practice runs more than 100 inbound consult inquiries a month and has no structured measurement of how many never reach a scheduled consultation, your pipeline is leaking revenue. We quantify this for your practice in a 30-minute Intake Leak Audit.

• Request an Intake Leak Audit: expand@thethinkingrobot.com

• Audit Real-Time Conversational Velocity: Talk to Rosey, our AI receptionist, at +1 (720) 776-1664.